Data of developmental pharmacokinetics (PK) of meropenem in critically ill infants and
children with severe infections are limited. We assessed the population PK and defined the …

Infections due to meropenem-nonsusceptible bacterial strains (MNBSs) with meropenem
minimum inhibitory concentrations (MICs)≥ 16 mg/L have become an urgent problem …

Background Nosocomial pneumonia due to antimicrobial-resistant pathogens is associated
with high mortality. We assessed the efficacy and safety of the combination antibacterial …

Objective: To test whether a prolonged 3-hour infusion of meropenem 500mg achieves an
equivalent proportion of time above the minimal inhibitory concentration (MIC)(% T MIC) to …

Importance Meropenem is a widely prescribed β-lactam antibiotic. Meropenem exhibits
maximum pharmacodynamic efficacy when given by continuous infusion to deliver constant …

Objective: To evaluate an intravenous meropenem dosage regimen in adult intensive care
patients with acute renal failure treated by continuous renal replacement therapy. Design: A …

Pseudomonas aeruginosa pneumonia remains a most-difficult-to-treat nosocomial bacterial
infection. We used mathematical modeling to identify drug exposure targets for meropenem …

OBJECTIVE This study aims to describe the population pharmacokinetics and
pharmacodynamic target attainment of meropenem in critically ill children. METHODS The …

Meropenem is a carbapenem antibacterial agent that has antimicrobial activity against Gram-
negative, Gram-positive and anaerobic micro-organisms. In vitro studies involving isolates …

Background: Meropenem is a broad-spectrum antibacterial that is usually used in the
treatment of serious lower respiratory tract infections (LRTIs). However, there is a lack of …